April 10, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares over potential securities laws violations by Corbus Pharmaceuticals Holdings and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) concerning whether a series of statements by Corbus Pharmaceuticals Holdings Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Corbus Pharmaceuticals Holdings Inc reported that its annual Total Revenue rose from $0.65 million in 2015 to $1.91 million in 2016.

Norwood, MA based Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company that is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases.

On March 30, 2017 Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum (fka JBT-101 or Resunab) compared to placebo for the treatment of patients with cystic fibrosis ('CF').

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) declined from $10.35 per share on March 20, 2017 to as low as $7.00 per share on April 7, 2017.